Диссертация (1154655), страница 23
Текст из файла (страница 23)
Macarie, O. Chioncel // Eur Heart JAcute Cardiovasc Care. – 2013. - vol.2(2). - p.99-108.60. Ambrosy, A.P. The global health and economic burden of hospitalizations for heartfailure: lessons learned from hospitalized heart failure registries / A.P. Ambrosy, G.C.Fonarow, J. Butler, et al.
// J Am Coll Cardiol. – 2014. – vol. 63. – p. 1123–1133.61. Arena, U. Acute viral hepatitis increases liver stiffness values measured by transientelastography / U.Arena, F. Vizzutti, G.Corti, S.Ambu, C.Stasi, S. Bresci, et al. //Hepatology.- 2008.-vol.47. – p.380-384.62. Bankir, L. Extracellular cAMP inhibits proximal reabsorption: are plasma membranecAMP receptors involved? / L.
Bankir, M. Ahloulay, P. Devreotes, C.Parent // Am JPhysiol Renal Physiol.- 282. F.376–392.63. Bansal, S Sodium retention in heart failure and cirrhosis: potential role of natriureticdoses of mineralocorticoid antagonist? / S. Bansal, J. Lindenfeld, R.W.
Schrier // CircHeart Fail. – 2009. –vol.2. – p. 370.64. Bayraktar, U. Hepatic venous outflow obstruction: Three similar syndromes. WorldJournal of Gastroenterology, 13(13), p.1912.65. Bennett, R.G. Degradation of relaxin family peptides by insulin-degrading enzyme /R.G. Bennett, D.G.
Heimann, F.G. Hamel // Ann N Y Acad Sci.- 2009. – vol.1160. –p.38–41.66. Benowitz, N.L. Pharmacokinetics in patients with cardiac failure / N.L. Benowitz, W.Meister // Clin Pharmacokinet. – 1976. – vol. 1. – p.389–405.67. Biegus, J. Abnormal liver function tests in acute heart failure: relationship withclinical characteristics and outcome in the PROTECT study / J.
Biegus, H.L. Hillege, D.128Postmus, M.A. Valente, D.M. Bloomfield, J.G. Cleland, G. Cotter, B.A. Davison, H.C.Dittrich, M. Fiuzat, M.M. Givertz, B.M. Massie, M. Metra, J.R. Teerlink, A.A. Voors,C.M. O'Connor, P. Ponikowski // Eur J Heart Fail . – 2016. - vol.18(7). – p. 830-839.68. Biegus, J. Liver function tests in patients with acute heart failure / J. Biegus, R.Zymlinski, M. Sokolski, S. Nawroc, P. Siwolowski, J. Szachniewicz, et al. // PolskieArchiwum Medycyny Wewnetrznej. – 2012. – vol. 122(10).
- p.471-479.69. Billebeau, G. Effects of serelaxin on a systolic cardiac dysfunction induced byisoproterenol in mice with increased cardiac aldosterone / G. Billebeau, M. Prud’homme,M. Sadoune et al. // European Journal of Heart Failure. – 2016. – vol. 18(Suppl. 1). – p.8.70.
Binanay, C.I. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluationstudy of congestive heart failure and pulmonary artery catheterization effectiveness: theESCAPEtrial / C.I. Binanay, R.M. Califf , V. Hasselblad, C.M. O'Connor, M.R. Shah, G.Sopko, L.W. Stevenson, G.S. Francis, C.V. Leier, L.W. Miller // JAMA. – 2005. – vol.294(13). – p. 1625-1633.71. Bjerkelund, C.J. Hypoprothrombinemia; occurrence and prognostic significance incongestive heart failure / C.J. Bjerkelund, E. Gleditsch // Acta Med Scand. - 1953.
– vol.145. – p. 181–188.72. Boehnert, M.U. Relaxin as a protective substance in the preserving solution for livertransplantation: spectrophotometric in vivo imaging of local oxygen supply in an isolatedperfused rat liver model / M.U. Boehnert, F.P. Armbruster, H. Hilbig // Ann N Y AcadSci. – 2009. – vol.1160. – p.320 – 321.73. Braunstein, J.
Noncardiac comorbidity increases preventable hospitalizations andmortality among medicare beneficiaries with chronic heart failure / J. Braunstein, G.Anderson, G. Gerstenblith, W. Weller, M. Niefeld, R. Herbert and A. Wu // Journal ofthe American College of Cardiology. – 2003. –vol. 42(7). - p. 1226- 1233.74. Brisco, M. Biochemical Evidence of Mild Hepatic Dysfunction IdentifiesDecompensated Heart Failure Patients With Reversible Renal Dysfunction / M.
Brisco,B. McCauley, J. Chen, C. Parikh and J. Testani // Journal of Cardiac Failure. - 2013. vol. 19(11). - p. 739 -745.12975. Brisco, M.A. Evidence of Mild Liver Dysfunction Identifies Stable Heart FailureOutpatients with Reversible Renal Dysfunction / M.A. Brisco, S.J. Cheng, O. Laur, A.J.Kula, J.M. Testani // Cardiorenal Med. – 2015. – vol.5.
– p.229–236.76. Bureau, C. Transient elastography accurately predicts presence of significant portalhypertension in patients with chronic liver disease / C. Bureau, S. Metivier, J.M. Peron,et al. // Aliment Pharmacol Ther. – 2008. – vol. 27(12). – p. 1261–1268.77. Cannon, J.A.
What can we learn from RELAX-AHF compared to previous AHF trialsand what does the future hold? / J.A. Cannon, A.R. McKean, P.S. Jhund, J. J. VMcMurray // Open Heart. – 2015. – vol.2(1) -:e000283. - p.1-12.78. Cannon, R.M. A review of the United States experience with combined heart-livertransplantation / R.M. Cannon, M.G. Hughes, C.M. Jones, M. Eng, M.R. Marvin //Transpl Int. – 2012. – vol. 25. – p. 1223-8.79. Castera, L. Non-invasive assessment of liver fibrosis: are we ready? / L.
Castera, M.Pinzani // Lancet. – 2010. – vol. 375. –p. 1419–1420.80. Castera, L. Prospective comparison of transient elastography, Fibrotest, APRI, andliver biopsy for the assessment of fibrosis in chronic hepatitis C / L. Castera, J. Vergniol,J. Foucher, et al. // Gastroenterology. – 2005. – vol. 128(2). – p. 343–350.81. Castera, L. Non-invasive evaluation of liver fibrosis using transient elastography / L.Castera, X .Forns, A.Alberti // J Hepatol. – 2008.
– vol. 48. –p.835– 847.82. Chalasani, N.P. Practice Parameters Committee of the American College ofGastroenterology. ACG Clinical Guideline: the diagnosis and management ofidiosyncratic drug-induced liver injury / N.P . Chalasani, P .H. Hayashi, H.L. Bonkovsky,V.J. Navarro, W.M. Lee, R.J. Fontana // Am J Gastroenterol. – 2014. – vol. 109(7). – p.950-966.83. Chokshi, A. Hepatic dysfunction and survival after orthotopic heart transplantation:application of the MELD scoring system for outcome prediction / A. Chokshi, F.H.Cheema, K.J. Schaefle, et al.
// J Heart Lung Transplant. – 2012. – vol.31. – p. 591–600.84. Cohen, J.A. Left-sided heart failure presenting as hepatitis / J.A. Cohen, M.M. Kaplan// Gastroenterology. – 1978. – vol.74. – p. 583–587.85. Colli A. / Decompensated chronic heart failure: increased liver stiffness measured by130means of transient elastography.
Colli A., Pozzoni P., Berzuini A. et al. // Radiology 2010.- 257(3). – p.872 - 888.86. Committee for medicinal products for human use (CHMP) guideline onimmunogenicity assessment of biotechnology-derived therapeutic proteins, 13 december200787. Connolly, S.J. Dabigatran versus warfarin in patients with atrial fibrillation / S.J.Connolly, M.D. Ezekowitz, S. Yusuf, et al. // N Engl J Med. – 2009. – vol. 361. – p.1139–1151.88. Cooper, L.B.
The Impact of Worsening Heart Failure in the United States / L.B.Cooper, A.D. DeVore, G.M. Felker // Heart Failure Clin. – 2015. – vol. 11. – p.603– 614.89. Cotter, G. Increased mortality after an acute heart failure episode: newpathophysiological insights from the RELAX-AHF study and beyond / G. Cotter, O.Milo, B.A. Davison // Curr Heart Fail Rep.
– 2014. – vol.11(1). – p. 19-30.90. Crespo-leiro, M. Reversal of cardiac cirrhosis following orthotopic hearttransplantation / M. Crespo-leiro, O. Robels, M. Paniagua, et al. // Am J Transplant. –2008. –vol. 8(6). – p. 1336-1339.91. Damman, K.
Decreased cardiac output, venous congestion and the association withrenal impairment in patients with cardiac dysfunction / K. Damman, G. Navis, T. Smilde,A. Voors, W. van der Bij, D. van Veldhuisen and H. Hillege // European Journal of HeartFailure . – 2007. – vol. 9(9). -p.872-878.92.
Dichtl, W. Cardiac hepatopathy before and after heart transplantation / W. Dichtl, W.Vogel, K. Dunst, et al. // Transpl Int. – 2005. – vol.18(6). – p. 697-702.93. Díez, J. Serelaxin for the treatment of acute heart failure: a review with a focus onend-organ protection / J. Díez, L.M.
Ruilope // Eur Heart J Cardiovasc Pharmacother. –2016. – vol. 2(2). – p.119-130.94. Doi, K. Impact of acute kidney injury on distant organ function: recent findings andpotential therapeutic targets / K. Doi and H. Rabb // Kidney International. – 2016. doi:10.1016/ j.kint.2015.11.019.95. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2016, European Heart Journal – doi:10.1093/eurheartj/ehw12813196. European Association for the Study of the Liver.
EASL Clinical Practice Guidelines:management of hepatitis C virus infection. J Hepatol. – 2011. – vol.55. – p.245–264.97. European Medicine Agency (EMA), Committee for Medicinal Products for HumanUse // EMA, Assessment report, Reasanz (international non-proprietary name: serelaxin),22 May 201498. Ford R. M., Wendy Book, James R. Spivey Liver disease related to the hear.Transplantation Reviews 2015; 29:33–37. doi:10.1016/j.trre.2014.11.00399.
Fuhrmann, V. Hypoxic hepatitis: underlying conditions and risk factors for mortalityin critically ill patients / V. Fuhrmann, N. Kneidinger, H. Herkner, et al. // Intensive CareMed. – 2009. – vol.35. –p.1397–1405.100. Gassanov, N. Cirrhotic cardiomyopathy: a cardiologist's perspective / N. Gassanov,E. Caglayan, N. Semmo, G.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
